在喘-COPD重叠中,杜皮卢马布治疗和三维支气管树变化重叠
Yoshiro Kai1,2, Yuichi Hishida3
1Department of Respiratory Medicine, Minami-Nara General Medical Center, Nara, Japan.
The journal of allergy and clinical immunology. Global
|July 29, 2025
概括
杜皮卢马布可以改善喘-COPD重叠的患者的肺功能和运动能力. 三维支气管树成像有助于评估这种疾病的治疗反应.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
背景情况:
- 喘-慢性阻塞性肺病 (COPD) 重叠带来复杂的呼吸系统挑战.
- 了解这种患者群体的治疗疗效对于改善治疗结果至关重要.
研究的目的:
- 评估dupilumab在改善喘-COPD重叠患者的肺功能和运动耐受性的疗效.
- 评估三维支气管树可视化在监测治疗反应中的有用性.
主要方法:
- 一项涉及被诊断患有喘-COPD的患者的研究重叠.
- 杜比卢马布治疗的使用.
- 使用三维支气管树可视化进行评估.
主要成果:
- 杜皮卢马布治疗在增强肺功能方面显示出潜在的益处.
- 在接受Dupilumab治疗的患者中观察到运动耐受性的改善.
- 三维支气管树可视化在评估治疗后的功能变化方面非常有价值.
结论:
- 杜皮卢马布可能是管理喘-COPD重叠的可行的治疗选择.
- 三维支气管树可视化是评估这些患者治疗结果的有益工具.
相关概念视频
COPD: Management Using Bronchodilators and Corticosteroids
314
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
314
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
Asthma-III: Symptoms and Complications
2.6K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
464
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
464
Antiasthma Drugs: Leukotriene Modifiers
482
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
482


